结直肠癌术后贫血:单剂羧基麦芽糖铁对比分次蔗糖铁随机对照试验方案
针对结直肠癌术后贫血患者,设计开放标签随机对照试验,比较单剂1000 mg羧基麦芽糖铁与分次蔗糖铁200 g/48 h的疗效。主要终点为术后第1天至第30天血红蛋白变化,每组计划48例,以检测0.75 g/dL差异。
要点
- 比较单剂羧基麦芽糖铁与分次蔗糖铁治疗结直肠癌术后贫血的疗效。
- 主要终点为术后第1天至第30天血红蛋白变化。
- 每组48例可检测血红蛋白变化差异0.75 g/dL。
核心结论
- 该试验将验证单剂1000 mg羧基麦芽糖铁是否应优先于分次蔗糖铁用于结直肠癌术后贫血。
研究设计与样本
- 开放标签随机对照试验,纳入年龄>18岁、行结直肠癌手术且术后第1天血红蛋白<11 g/dL的患者。
- 患者随机接受单剂1000 mg羧基麦芽糖铁或分次蔗糖铁200 g/48 h治疗。
- 每组计划纳入48例患者,以检测术后第1天至第30天血红蛋白变化差异0.75 g/dL。
关键数值与推荐
- 主要终点为术后第1天至第30天血红蛋白水平变化。
- 关键次要终点为术后第30天血红蛋白水平≥13 g/dL的患者比例。
- 其他次要终点包括铁代谢参数变化、铁总剂量、术后输血次数、口服铁治疗依从性、并发症、不良反应、健康资源使用和生活质量变化。
临床怎么用
- 研究结果将指导结直肠癌术后贫血的静脉铁剂选择,明确单剂羧基麦芽糖铁是否可优先使用及适用患者类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with colorectal cancer (CRC) often present with associated anaemia which is usually present at the time of diagnosis and is aggravated during the postoperative period due to blood loss during the surgery process. Several guidelines advocate for the treatment of postoperative anaemia in these patients in order to prevent complications and allogeneic blood transfusions. However, there are no publications to shed light on the effectiveness of intravenous iron (IVI) administration after CRC surgery and the optimal dose and regimen. We have started a clinical trial with the objective of comparing the effectiveness of 1000 mg of ferric carboxymaltose with fractionated iron sucrose 200 g/48 h for the treatment of postoperative anaemia, by measuring the change of haemoglobin (Hb) levels from postoperative day (POD) 1 to POD 30. METHODS: We designed an open label randomised controlled trial to compare two postoperative IVI treatment regimens. Patients aged > 18 years undergoing CRC surgery, with Hb < 11 g/dL on POD 1 are randomly assigned to receive either 1000 mg of ferric carboxymaltose (single dose) or 200 g/48 h of iron sucrose. The main study endpoint will be the change from POD 1 to POD 30 in Hb levels and the key secondary endpoint the percentage of patients with Hb levels ≥ 13 g/dL at POD 30. Other secondary endpoints include: changes in iron metabolism parameters (Fe, ferritin, transferrin, % saturated trasferrin) at POD 30; total doses of iron received; number of postoperative transfusions; compliance with oral iron treatment; number of medical and surgical complications; adverse reactions reported by the patient; use of health resources after surgery; and changes in quality of life (QoL). It has been estimated that a sample of 48 patients per group will allow detecting a difference of 0.75 g/dL in Hb in the change in Hb levels from POD 1 to POD 30. DISCUSSION: The results of this study will confirm if the single dose of 1000 mg ferric carboxymaltose should be preferred in front of the fractionated doses and in which type of patients this regimen should be used preferably. TRIAL REGISTRATION: European Union Clinical Trials Register, EudraCT 2015-001005-13 . Registered on 6 January 2015.
引用
- Laso-Morales MJ, Vives R, Vallejo-Tarrat A, et al. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial. Trials. 2019. PMID: 30616657. doi:10.1186/s13063-018-3125-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。